Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Well Corp (AMWL) vs ResMed Inc. (RMD) Price & Performance

American Well CorpTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

American Well Corp vs ResMed Inc. — how do they compare? American Well Corp trades at $12.95 (market cap $220.94M), while ResMed Inc. trades at $223.61 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 147.6× American Well Corp's market cap, and ResMed Inc. pays a 1.17% dividend while American Well Corp pays none. Which is the better fit depends on your goals.

AMWLRMD
Market Cap
$220.94M$32.61B
Sector
HealthHealth
52-Week High
$13.58$293.73
52-Week Low
$3.78$182.82
Enterprise Value
$27.98M$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Well Corp

AMWL trades at $13.58, up 0.44% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $52 million, beating estimates, and continues to narrow losses. Recent news includes a key executive joining Amazon's healthcare unit, potentially opening partnership opportunities.

The outlook is cautiously optimistic as AMWL progresses toward cash-flow breakeven, but persistent net losses and negative margins pose risks. Analyst consensus is mixed, with 33% buy ratings, reflecting uncertainty around profitability timelines amid competitive pressures.

ResMed Inc.

ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.

The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Well Corp

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.

Read more on AMWL

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD